Isoflavonoid compositions and methods for the treatment of cancer
Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
1. A pharmaceutical composition consisting essentially of:
i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol;
ii) SBE7-β-CD; and
iii) a liquid vehicle.
2. The composition of claim 1 , wherein SBE7-β-CD has a concentration (w/v) ranging from about 0.001% to about 50%.
3. The composition of claim 1 , wherein SBE7-β-CD has a concentration (w/v) ranging from about 28% to about 32%.
4. The composition of claim 1 , wherein the liquid vehicle is sterile water, Ringer's solution, phosphate buffered saline solution, isotonic sodium chloride solution, ethanol, or 1,3-butanediol.
5. The composition of claim 1 , wherein the liquid vehicle is sterile water.
6. The composition of claim 1 , wherein d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol is present in an amount of about 0.2-50 mg/mL.
7. The composition of claim 1 , wherein d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol is present in an amount of about 25-40 mg/mL.
8. The composition of claim 1 , wherein the composition is formulated for intravenous administration.
9. A method of treating cancer in an individual in need of cancer therapy, the method comprising administering to the individual a composition consisting essentially of:
i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol;
ii) SBE7-β-CD; and
iii) a liquid vehicle.
10. The method of claim 9 , wherein the composition increases or induces sensitivity of the cancer to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.
11. The method of claim 10 , wherein the cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.
12. The method of claim 9 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, and cancers of the brain.
13. The method of claim 9 , wherein said cancer is human breast cancer or ovarian cancer.
14. The method of claim 9 , further comprising administering a chemotherapeutic agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, and doxorubicin.
15. A kit comprising a sealable, plastic infusion bag; and a composition consisting essentially of:
i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol;
ii) SBE7-β-CD; and
iii) a liquid vehicle.